ARK Genomic Revolution ETF (BATS:ARKG) Shares Sold by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC cut its stake in shares of ARK Genomic Revolution ETF (BATS:ARKG) by 17.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 32,358 shares of the company’s stock after selling 6,910 shares during the quarter. Wealth Enhancement Advisory Services LLC owned about 0.07% of ARK Genomic Revolution ETF worth $762,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Hemington Wealth Management grew its stake in ARK Genomic Revolution ETF by 44.6% in the 4th quarter. Hemington Wealth Management now owns 1,310 shares of the company’s stock valued at $30,000 after acquiring an additional 404 shares during the last quarter. Avantax Advisory Services Inc. grew its stake in ARK Genomic Revolution ETF by 2.5% in the 4th quarter. Avantax Advisory Services Inc. now owns 28,701 shares of the company’s stock valued at $676,000 after acquiring an additional 702 shares during the last quarter. Rockefeller Capital Management L.P. grew its stake in ARK Genomic Revolution ETF by 13.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 12,150 shares of the company’s stock valued at $286,000 after acquiring an additional 1,439 shares during the last quarter. Baird Financial Group Inc. grew its stake in ARK Genomic Revolution ETF by 21.1% in the 4th quarter. Baird Financial Group Inc. now owns 10,127 shares of the company’s stock valued at $238,000 after acquiring an additional 1,765 shares during the last quarter. Finally, Union Bancaire Privee UBP SA acquired a new stake in ARK Genomic Revolution ETF in the 4th quarter valued at about $45,000.

ARK Genomic Revolution ETF Price Performance

Shares of BATS ARKG opened at $24.23 on Wednesday. ARK Genomic Revolution ETF has a 52 week low of $17.51 and a 52 week high of $31.16. The company’s 50-day moving average price is $21.33 and its 200 day moving average price is $23.69.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.